Two different markers of oxidative protein damage in plasma of alloxan-induced hyperglycemic rabbits: effects of pioglitazone and repaglinide. Oxidative protein damage and two antidiabetics
DOI:
https://doi.org/10.12923/j.2084-980X/25.2/a.01Keywords:
experimental hyperglycemia, oxidative/nitrosative stress, oxidized proteins, antidiabeticsAbstract
Reactive oxygen and nitrogen species are known to contribute to different pathological alterations in hyperglycemic state. Especially proteins are major targets resulting from their rapid reactions with many oxidants. Therefore, the present study was undertaken to examine some common markers of oxidative/nitrosative stress in plasma of alloxan-induced hyperglycemic rabbits with special regard to protein oxidation. The second goal was to investigate which of two antidiabetics, pioglitazone from peroxisome proliferator-activated receptor gamma agonists, and repaglinide from non-sulfonylurea KATP channel blockers, could be more effective in ameliorating these oxidative/nitrosative changes. In our hyperglycemic animals glutathione decreased by 41% as compared to control group. Simultaneously, lipid peroxidation products increased by 62%, nitrites by 59%, protein carbonyl groups by 71% and advanced oxidized protein products by 53%. In hyperglycemic-treated animals pioglitazone increased glutathione above control values. In turn, lipid peroxidation was reduced by 29%, nitrites by 22%, advanced oxidized protein products by 37% and protein carbonyl groups by 42% in relation to hyperglycemic-non treated rabbits. After repaglinide treatment, lipid peroxidation decreased by 17% but the levels of glutathione, nitrites and both markers of oxidized proteins, were not affected. Our results confirmed that the action of pioglitazone is more comprehensive than that of repaglinide, independently of their action on hyperglycemia.
References
1. Stadler K., Bonini M.G., Dallas S., Jiang J., Radi R.: Involvement of inducible nitric oxide synthase in hydroxyl radical mediated lipids peroxidation in streptozotocin-induced diabetes. Free Radic. Biol. Med. 45, 866, 2008.
2. Breusing N., Grune T.: Biomarkers of protein oxidation from a chemical, biological and medical point of view. Exp. Gerontol. 45, 733, 2010.
3. Pandey K.B., Mishra N., Rizvi S.I.: Protein oxidation biomarkers in plasma of type 2 diabetic patients. Clin. Biochem. 43, 508, 2010.
4. Witko-Sarsat V.M., Friendlander C., Capeillere-Blandin C., Nguyen-Khoa T., Nguen A.T., Zingraff J., Jungers P., Descamps-Latscha B.: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49, 1304, 1996.
5. Martin-Gallan P., Carrascosa A., Gussinye M., Dominguez C.: Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic. Biol. Med. 34, 1563, 2003.
6. Chakraborty A., Chowdhury S., Bhattacharyya M.: Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes. Diabetes Res. Clin. Pract. 93, 56, 2011.
7. Telci A., Cakatay U., Salman S., Satman I., Sivas A.: Oxidative protein damage in early stage type 1 diabetic patients. Diabetes Res. Clin. Pract. 50, 213, 2000.
8. Gross B., Staels B.: PPAR agonists: multimodal drugs for the treatment of type 2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 2, 687, 2007.
9. Inoue I., Goto S., Matsunaga T., Nakajima T., Awata T., Hokari S., Komoda T., Katayama S.: The ligands/activators for peroxisome proliferator-activated receptor α (PPARα) and PPARγ increase Cu+2,Zn+2-superoxide dismutase and decrease p22phox message expression in primary endothelial cells. Metabolism 50, 3, 2001.
10. Vinik A.I., Ullm J., Parson H.K., Barlow P.M., Casellini C.M.: Pioglitazone treatment improves nitrosative stress in type 2 diabetes. Diabetes Care 29, 869, 2006.
11. King D.E., King M., Player M.S., Everett C.J.: The impact of pioglitazone on ADMA and oxidative stress markers in patients with type 2 diabetes. Prim. Care Diabetes 2011; doi: 10.1016/j.pcd.2011.06.002
12. Kumar A., Vashist A., Kumar P.: Potential role of pioglitazone, caffeic acid and their combination against fatigue syndrome-induced behavioral, biochemical and mitochondrial alterations in mice. Inflammopharmacology 18, 241, 2010.
13. Majithija J.B., Paramar A.N., Balaraman R.: Pioglitazone, a PPARγ agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc. Res. 66, 150, 2005.
14. Manzella D., Abbatecola A.M., Grella R., Paolisso G.: Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 28, 366, 2005.
15. Tankova T., Koev D., Dakovska L., Kirilov G.: The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes Res. Clin. Pract. 59, 43, 2003.
16. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J.: Protein measurement with Folin phenol reagent. J. Biol. Chem. 193, 265, 1951.
17. Bhatia S., Bhatia R., Shukla S., Venkata Madhu S., Kaur Gambhir J., Madhava Prabhu K.: Antioxidant status, lipid peroxidation and nitric oxide end products in patients of type 2 diabetes mellitus with nephropathy. Clin. Biochem. 36, 557, 2003.
18. Kalousova M., Skrha J., Zima T.: Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 51, 597, 2002.
19. Piwowar A., Knapik-Kordecka M., Warwas M.: AOPP and its relations with selected marker of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 77, 188, 2007.
20. Gumieniczek A., Hopkała H., Roliński J., Bojarska-Junak A.: Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. Pharmacol. Res. 52, 162, 2005.
21. Gumieniczek A., Hopkała H., Roliński J., Bojarska-Junak A.: Interleukin-6 and oxidative stress in plasma of aloxan-induced diabetic rabbits after pioglitazone treatment. Immunopharmacology 28, 81, 2006.
22. Levine R.L., Williams J.A., Stadtman E.R., Shacter E.: Carbonyl assays for determination of oxidatively modified proteins. Method Enzymol. 233, 346, 1994.
23. Witko-Sarsat V.M., Gausson B., Descamps-Latscha B.: Are advanced oxidation protein products potential uremic toxins. Kidney Int. 63, S11-S14, 2003.
24. Ananthan R., Baskar C., NarmathaBai V., Pari L., Latha M., Ramkumar K.M. Antidiabetic effect of Gymnema montanum leaves: effect on lipid peroxidation induced oxidative stress in experimental diabetes. Pharmacol. Res. 48, 551, 2003.
25. Skrha J., Prazny M., Hilgertova J., Weiserova H.: Serum a-tocopherol and ascorbic acid concentrations in type 1 and type 2 diabetic patients with and without angiopathy. Clin. Chim. Acta 329, 103, 2003.
26. De Matia G., Laurenti O., Fava D.: Diabetic endothelial dysfunction. Effect of free radical scavenging in type 2 diabetic patients. J. Diabetes Complicat. 17, 30, 2003.
27. Livingstone C. Davis J.: Targeting therapeutics against glutathione depletion in diabetes and its complications. Br. J. Diabetes Vasc. 7, 258, 2007.
28. Pereira E.C., Ferderbar S., Bertolami M.C., Faludi A.A., Monte O., Xavier H.T., Pereira T.V., SaesParra Abdalla D.: Biomarkers of oxidative stress and endothelial dysfunction in glucose intolerance and diabetes mellitus. Clin. Biochem. 41, 1454, 2008.
29. Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dantona P.: Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action. J. Clin. Endocrinol. Metab. 2001; 86: 3250-3256
30. Villegas I., Ramon-Martin A., Toma W., Alarcon de la Lastra C.: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation. Eur. J. Pharmacol. 505, 195, 2004.
31. Sung B., Park S., Yu B.P., Hung H.Y.: Amelioration of age-related inflammation and oxidative stress by PPARγ activator: Suppression of NF-κB by 2,4-thiazolidinedione. Exp. Gerontol. 41, 590, 2006.
32. Tao L., Liu H., Gao E., Teng Z., Lopez B.L., Christopher T.A., Ma X., Batinic-Haberle I., Willette R.N., Ohlstein E.H., Yue T.: Antioxidative, antinitrative and vasculoprotective effects of a peroxisome proliferator-activated receptor γ agonist in hypercholesterolemia. Circulation 108, 2805, 2003.
33. Gumieniczek A., Komsta Ł., Rachid Chehab M.: Effects of two oral antidiabetics, pioglitazone and repaglinide, on aconitase inactivation, inflammation and oxidative/nitrosative stress in tissues under alloxan-induced hyperglycemia. Eur. J. Pharmacol. 659, 89, 2011.
34. Gumieniczek A., Krzywdzińska M., Nowak M.: Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide. Exp. Lung Res. 35, 371, 2009.
35. Da Silva-Santos J.E., Santos-Silva M.C., Cunha F., Assreuy J.: The role of ATP-sensitive Potassium channels in neutrophil migration and plasma exudation. J. Pharmacol. Exp. Ther. 300, 946, 2002.
36. Assaloni R., Da Ros R., Quagliaro L., Piconi L., Maier A., Zuodar G., Motz E., Ceriello A.: Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 48, 1919, 2005.
37. Li Y., Xu L., Shen J., Ran J., Zhang Y., Wang M., Yan L., Cheng H., Fu Z.: Effect of short-term therapy with different insulin secretagogue on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed type 2 diabetes mellitus. Diabetes Res. Clinical Pract. 88, 42, 2010.
38. Pop-Busui R., Oral E, Raffel D., Byun J., Bajirovis V., VivekanandanGiri A., Kellogg A., Pennathur S., Stevens MJ.: Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. Metab. Clin. Exp. 58, 989, 2009.
Downloads
Published
Issue
Section
License
Copyright (c) 2012 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
